Compare OBIO & CMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OBIO | CMT |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | 1239 |
| Industry | Medicinal Chemicals and Botanical Products | Electronic Components |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.7M | 203.8M |
| IPO Year | 2020 | 1996 |
| Metric | OBIO | CMT |
|---|---|---|
| Price | $3.92 | $23.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $14.25 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 213.9K | 19.2K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.13 | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | $33,482,000.00 | ★ $284,290,000.00 |
| Revenue This Year | N/A | $4.58 |
| Revenue Next Year | $12.43 | $6.04 |
| P/E Ratio | ★ N/A | $334.57 |
| Revenue Growth | ★ 1169.22 | 5.49 |
| 52 Week Low | $2.20 | $16.37 |
| 52 Week High | $5.42 | $28.69 |
| Indicator | OBIO | CMT |
|---|---|---|
| Relative Strength Index (RSI) | 46.70 | 46.53 |
| Support Level | $3.77 | $22.74 |
| Resistance Level | $4.18 | $25.20 |
| Average True Range (ATR) | 0.19 | 0.96 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 37.50 | 33.51 |
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.